Erythromycin Eplerenone

Clinically important, potentially hazardous interactions with alprazolam, amphotericin B, anisindione, anticoagulants, dicumarol, eplerenone, erythromycin, methadone, midazolam, phenobarbital, phenytoin, ramelteon, sulfonylureas, trabectedin, vinblastine, vincristine, warfarin... 

Clinically important, potentially hazardous interactions with alfuzosin, alprazolam, amphotericin B, anisindione, antacids, aprepitant, astemizole, atorvastatin, bosentan, ciclesonide, cimetidine, clorazepate, conivaptan, cyproterone, dasatinib, dexamethasone, dicumarol, didanosine, eplerenone, erythromycin, ethotoin, fentanyl, fesoterodine, fosamprenavir, fosphenytoin, grapefruit juice, HMG-CoA reductase inhibitors, imatinib, ixabepilone, lapatinib, lopinavir, lovastatin, mephenytoin, methylprednisolone, micafungin, midazolam, nilotinib, pimozide, prednisolone, prednisone, quinidine, rifampin, rimonabant, rivaroxaban, sildenafil, silodosin, simvastatin, sirolimus, solifenacin, temsirolimus, terfenadine, tolvaptan, triazolam, vardenafil, vinblastine, vincristine, warfarin... 

Clinically important, potentially hazardous interactions with acebutolol, amiodarone, aspirin, atenolol, atorvastatin, betaxolol, carbamazepine, carteolol, celiprolol, donidine, dabigatran, dantrolene, digoxin, dofetilide, epirubicin, eplerenone, erythromycin, esmolol, eucalyptus, everolimus, lovastatin, metoprolol, mistletoe, nadolol, oxprenolol, penbutolol, pindolol, propranolol, quinidine, ranolazine, sibutramine, simvastatin, timolol, trabectedin... 

POTASSIUM-SPARING DIURETICS MACROUDES -ERYTHROMYCIN T eplerenone results in an T risk of hypotension and hyperkalaemia Eplerenone is primarily metabolized by CYP3A4 there are no active metabolites. Erythromydn moderately inhibits CYP3A4, leading to T levels of eplerenone Dosage should not exceed 25 mg daily... 

In the UK, the manufacturers recommend that the dose of eplerenone should not exceed 25 mg daily in patients taking mild to moderate CYP3A4 inhibitors such as amiodarone, diltiazem, erythromycin, fluconazole, saquinavir and verapamil. In the US, the manufacturer recommends that the starting dose for hypertension should be reduced to 25 mg daily for patients taking these drugs. This seems a sensible precaution. However, note that in many cases erythromycin appears to be a more potent inhibitor of CYP3A4 than clarithromycin (and certainly the other moderate CYP3A4 inhibitors listed above), and so extra caution is probably warranted with this combination. 

---